Comparing measured and reported change in gastrointestinal symptoms after initiation of metformin treatment: a questionnaire validation studyShow others and affiliations
2026 (English)In: Scandinavian Journal of Primary Health Care, ISSN 0281-3432, E-ISSN 1502-7724, Vol. 44, no 1, p. 1-9
Article in journal (Refereed) Published
Abstract [en]
BACKGROUND: The majority of individuals in Sweden with type 2 diabetes have their sole health care provider in primary health care. Metformin treatment often causes gastrointestinal side-effects. Our aim was to construct and validate a questionnaire assessing gastrointestinal symptoms before and after starting metformin treatment for type 2 diabetes.
METHODS: In the Interaction Between Metformin and Microbiota (MEMO) study, 54 participants rated six gastrointestinal symptoms at baseline and after 2 months of metformin treatment in a questionnaire (measured change, i.e. the difference between assessments at these two time points), as well as direct assessment of perceived change in symptoms after 2 months in a separate validation questionnaire (reported change, i.e. how participants themselves have perceived the change between the same two time points). Spearman's ρ was calculated and reported with its 95% CI.
RESULTS: The agreement between reported and measured change of symptoms, measured as Spearman's ρ, was above 0.4 for 4 out of 6 symptoms (poor appetite 0.60 [95% CI 0.39-0.75], loose stool or diarrhea 0.58 [95% CI 0.37-0.74], flatulence 0.45 [95% CI 0.21-0.64], and abdominal pain 0.45 [95% CI 0.20-0.65]). The agreement was lower for nausea and vomiting, although these were numerically above 75% in agreement, likely due to few symptomatic participants overall.
CONCLUSION: For common side-effect symptoms associated with metformin treatment, our study shows that symptom change measured as the difference between assessments at two different time-points was in overall agreement, validating the usability of the constructed questionnaire for metformin side-effects.
Place, publisher, year, edition, pages
Taylor & Francis, 2026. Vol. 44, no 1, p. 1-9
Keywords [en]
Treatment side-effects, bowel symptoms, metformin, patient-reported outcome measure (PROM), primary health care, questionnaire
National Category
Endocrinology and Diabetes
Identifiers
URN: urn:nbn:se:oru:diva-125240DOI: 10.1080/02813432.2025.2592696ISI: 001622179700001PubMedID: 41283789Scopus ID: 2-s2.0-105022896396OAI: oai:DiVA.org:oru-125240DiVA, id: diva2:2016718
Funder
Region Östergötland, RÖ-9406402025-11-262025-11-262026-03-06Bibliographically approved